EssilorLuxottica Acquires Canadian Med-Tech Start-Up Cellview

EssilorLuxottica has acquired Cellview Imaging, a Canadian start-up specializing in diagnostic via retinal imaging. Financial terms of the deal were not disclosed.

Based in Toronto, Cellview designs and manufactures diagnostic imaging instruments. Currently distributed in North America, Cellview’s solutions allow eye care practitioners to diagnose retinal pathologies thanks to the ultra-widefield retinal camera capable of capturing significantly larger images compared to most existing technologies, according to EssilorLuxottica. Cellview’s product offering is FDA- and CE Mark-approved and targets a large market base—from eyecare practices in retail locations to ophthalmology clinics – and is set to be distributed in different geographies, starting with Europe.

“We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health. By integrating another pioneering company with strong expertise in R&D and world-class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need of vision health and the early diagnosis of retinal pathologies," Francesco Milleri, Chairman and CEO and Paul du Saillant, Deputy CEO at EssilorLuxottica, said in a company news release. "While our products and services remain accessible to all industry players–as a pillar of EssilorLuxottica’s open business model–we continue to elevate market standards, in full alignment with our journey into the med-tech space."